Figure 1.

VEGF-A quantification and PI3K activity in DLBCL patients treated with SOC R-CHOP or Ro+R-CHOP. (A) Left to right, fold change in urinary VEGF-A levels from baseline (before cycle 1—C1) to after the completion of two or five treatment cycles (at the start of cycle 3 or cycle 6, C3 or C6); nine Ro+R-CHOP- and six or seven R-CHOP-treated patients were included in these analyses. (B) Left to right, fold change in urinary VEGF-A levels from baseline (before cycle 1—C1) to after the completion of two or five treatment cycles (at the start of cycle 3 or cycle, C3 or C6); only non-GCB DLBCL patients and complete responders (CRs) were included in these analyses, with five Ro+R-CHOP- and three R-CHOP-treated patients. (C) Fold change in PI3K activity measured in the PBMCs of patients treated with Ro+R-CHOP, comparing the baseline (before cycle 1—C1) to after the completion of two treatment cycles (at the start of cycle 3—C3). Three patients with PR-R/R (partial responder–relapsed/refractory) who died of their disease are compared to four patients who achieved CR and remain free of disease (materials were not available for UPN#1, a complete responder and long-term survivor). (D) Fold change in PI3K activity measured in the PBMCs of patients treated with SOC R-CHOP, comparing the baseline (before cycle 1—C1) to after the completion of two treatment cycles (at the start of cycle 3—C3). Two patients in this series did not reach CR, and materials were not available for one of them. Data are mean ± SD. All data points quantified are shown (three replicates for each patient); p values are from two-sided Student’s t-test, * < 0.05, *** < 0.001, **** < 0.0001.